Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102

NCT00522665 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT00522665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2007
Completion date
February 28, 2015
Enrollment
41 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer